Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS S/AS01E (0.5 mL Dose) to RTS S/AS02D (0.5 mL Dose) Administered IM According to a 0 1 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years .

Trial Profile

Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS S/AS01E (0.5 mL Dose) to RTS S/AS02D (0.5 mL Dose) Administered IM According to a 0 1 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years .

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs GSK 257049 (Primary) ; AS01E; AS02
  • Indications Falciparum malaria
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Apr 2008 Status changed from in progress to completed.
    • 23 Apr 2008 Actual patient number (180) added as reported by ClinicalTrials.gov.
    • 13 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top